Health

Hantavirus ship heads to Netherlands after passengers flown home

You can share an article by clicking on the share icons at the top right of it.
The total or partial reproduction of an article, without the prior written authorization of Le Monde, is strictly forbidden.

The cruise ship hit by a deadly hantavirus outbreak headed to the Netherlands on Tuesday, May 12, after its last passengers disembarked in Spain’s Canary Islands, with at least seven of the evacuees testing positive for the virus. Three people died after the rare virus that usually spreads among rodents was detected on board the MV Hondius, sparking a global health scare. Among living patients, seven cases have been confirmed and an eighth is listed as “probable,” according to the World Health Organization (WHO).

French officials said one woman who tested positive was hospitalized and in stable condition in intensive care. No vaccines or specific treatments exist for the virus, but health officials have said the risk to the public is low and dismissed comparisons to the Covid-19 pandemic.

The Dutch-flagged ship was expected to arrive in Rotterdam on Sunday evening, according to its operator, where it will undergo disinfection procedures. More than 25 crew members and medical staff were still on board the ship, which is carrying the body of a German passenger who died during the voyage, but all passengers have now disembarked.

“Mission accomplished,” exulted Spanish Health Minister Monica Garcia Gomez, on the quay of the port of Granadilla de Abona, in Tenerife. “Between yesterday and today, we have evacuated the 125 passengers and crew members from 23 countries, who have either already returned home or are in the process of being repatriated. The ship, as you can see, has just weighed anchor. It left the port today at 7 pm,” she said.

The final cohort of 28 evacuees traveled on chartered buses to Tenerife South Airport and boarded two flights that landed in the Netherlands early on Tuesday. One plane carried mostly crew members – 17 Filipinos, a Dutch national and a German – as well as a British doctor and two epidemiologists. A second flight transported six other passengers – four Australians, a New Zealander and a Briton living in Australia – who would stay in a quarantine facility near the airport before being repatriated.

Wearing white medical overalls and fface masks, the evacuees disembarked from the air ambulance clutching white bags of their belongings and walked into Eindhoven airport’s terminal. Spanish authorities said the cruise ship, which was originally only authorized to anchor offshore for the evacuation on health and safety grounds, had docked in port because of unfavorable weather.

At a press conference at the port, WHO chief Tedros Adhanom Ghebreyesus, who is due to meet the Spanish prime minister in Madrid on Tuesday, sought to reassure the passengers. He said they were in good hands now and that the situation could have become difficult if they stayed on the ship but added that this “is not another Covid.”

Search for contacts

Among the completed repatriations, a French woman – one of five evacuees from France placed in isolation in Paris – started to feel unwell on Sunday night, and “tests came back positive,” Health Minister Stéphanie Rist said.

A Spanish passenger has also tested positive, the health ministry in Madrid said, adding that results for the 13 other Spanish evacuees were so far negative. Spain’s health ministry defended the rigour of the evacuations, where medical teams escorted passengers from the ship to an airport on Tenerife under close supervision and following health checks.

“From the start, all the measures adopted have aimed at cutting the possible chains of transmission… all measures for prevention and control of transmission have been applied,” it said in a statement. In total, seven cases have been confirmed among living passengers, health officials have said.

Other suspected cases and potential close contacts with infected people are being investigated, with health authorities in several countries tracking passengers who had already disembarked from the ship, plus anyone who may have come into contact with them.

In a video shared on Monday by operator Oceanwide Expeditions, captain Jan Dobrogowski paid tribute to the “unity and quiet strength” of everyone on board and highlighted the “courage and selfless resolve” of the crew.

The MV Hondius left Argentina, where hantavirus is endemic, on April 1 for a cruise across the Atlantic Ocean to Cape Verde. The WHO believes the first infection occurred before the start of the voyage, followed by transmission between humans on board the vessel. But Argentine health officials have questioned whether the outbreak originated in the southern city of Ushuaia, based on the virus’s weeks-long incubation period and other factors.

Le Monde

Health

Novartis: Rare muscle disease drug shows early promise

Novartis (NOVN.S), opens new tab said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of ‌Avidity, showed promise in an early-to-mid-stage study in patients with a type of genetic muscle disorder characterized by slowly progressive muscle weakness.

The Swiss ⁠drugmaker said the drug, known as del-brax, lowered two blood markers linked to the disease and showed reduced signs of muscle damage in patients with facioscapulohumeral muscular dystrophy.
Novartis said the drug shows potential to become the first disease-modifying ‌treatment ⁠for FSHD, which can cause weakness in the face, shoulders, arms and other muscles.
The company estimates it affects about 45,000 to ⁠87,000 people in the U.S. and EU.
The drug’s safety profile was consistent with previous ⁠results, the company said.
Novartis plans to discuss the data with health regulators ⁠around the world, while a late-stage study of the drug is currently enrolling patients.

The Thomson Reuters

Health

Obesity drug shows promise in reducing belly and liver fat

Boehringer Ingelheim said on Sunday its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in ‌a late-stage study, data showed, bolstering its case for benefits beyond weight loss as competition in obesity drugs intensifies.

The drug, survodutide, was licensed from Denmark’s Zealand Pharma (ZELA.CO), opens new tab. An injectable that mimics the proteins GLP-1 and glucagon to create a feeling of fullness, its weight-loss trial results were announced in April, showing patients lost an average of 16.6% over 76 weeks.

Analysis of a group of patients who had MRI measurements at the start and end of a 76-week trial showed that survodutide reduced harmful ⁠abdominal fat by up to 34% and liver fat by up to 63.1% from the baseline, Boehringer said.

Analysts have said the weight-loss numbers were broadly comparable to existing GLP-1 injections from Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab and below newer rivals in development, and that the company needed to differentiate the drug’s benefits.

Lean mass accounted for no more than 10.8% of the change in body composition at the highest dose of 6 milligrams, suggesting the weight loss was driven mainly by fat reduction.

The drug’s effect on liver-fat reduction and preservation of lean mass are central to whether it will be able to stand out commercially, alongside tolerability and how long patients stay on the drug. Detailed data from the study could help Boehringer make a ‌stronger case ⁠that survodutide should be judged not only by pounds lost but by where weight is lost.

“We believe survodutide will become an important new option at the intersection of obesity and liver disease, two conditions that are deeply connected but rarely addressed together,” said Boehringer executive Shashank Deshpande, who leads the company’s human medicines business.

Boehringer acquired the rights in 2011 to solely develop and commercialise survodutide from Zealand, which is ⁠entitled to royalty payments on global revenue.

PATIENTS WITH LIVER DISEASE BENEFIT

In a separate late-stage study of overweight or obese patients with a fatty liver disease called MASLD, survodutide met both its main goals.

After 48 weeks, up to 84.2% of patients on the drug showed ⁠a liver fat reduction of at least 30%, compared with 24.3% for those on placebo. Patients on survodutide also lost up to 12.2% of their body weight, versus 1% for placebo.

In 61% of the patients the drug helped achieve liver fat ⁠normalization, or a liver fat content below 5%, compared with 5.7% on placebo.

U.S. biotech Altimmune (ALT.O), opens new tab is also developing a drug that targets both the appetite-suppressing gut hormone, GLP-1, and glucagon.

Survodutide is also being tested in other late-stage studies, including for patients with fatty liver disease and fibrosis.

REUTERS

Health

Millions with breast cancer could safely skip chemotherapy

Millions of people with breast cancer could safely avoid chemotherapy as scientists have developed a DNA test that can distinguish between patients who are likely to benefit from the treatment and those who are not, according to trial results.

The international study found that more than two-thirds of its participants could be spared the side of effects of chemotherapy and treated with hormone therapy alone.

Chemotherapy can cause fatigue, nausea, hair loss, a weakened immune system and fertility issues.

The study, led by University College London (UCL), involved more than 4,000 newly diagnosed patients over the age of 40 in the UK, Norway, Sweden, Australia, New Zealand and Thailand.

Scientists used a gene test called Prosigna to measure the activity of 50 genes involved in breast cancer growth and calculate a patient’s risk of the disease returning.

Those who received a low score – two-thirds of the group – were not treated through chemotherapy. The five-year survival rate of their group was 93.7%, compared with a 94.9% rate among patients who received chemotherapy as part of their care.

The primary treatment for breast cancer is usually surgery to remove tumours. Chemotherapy is often recommended afterwards to diminish the risk of return.

It is also regularly offered to people with early-stage breast cancer that has spread to the nearby lymph nodes.

Clinicians are concerned the treatment provides little benefit to those with the most common type of breast cancer, UCL said.

The university said more than 5,000 NHS patients a year could avoid chemotherapy as a result of the trial.

Karen Bonham, from Cardiff, took part in the trial and said the results are an “immense relief” and feel “like Christmas”.

The 64-year-old avoided chemotherapy thanks to the Prosigna test and has instead received radiotherapy and hormone therapy over eight years.

“Cancer diagnosis and treatment can be shocking,” she said.

“It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive.”

The findings of the study will be presented at the world’s largest cancer conference, the American Society of Clinical Oncology’s annual meeting, in Chicago, United States, on Saturday.

Professor David Miles, a leading cancer specialist, described the findings as “practice-changing”.

“We can now confidently predict many patients will get no benefit at all, and therefore there’s no need for them to have the chemotherapy,” he told BBC’s Newshour.

He added that the test would allow doctors to “confidently define a large population of women who simply aren’t going to benefit and don’t need to go through all that unpleasantness for no benefit at all.”

“We used to give chemotherapy to 100 women to benefit 10, knowing that 90 didn’t need it,” he said.

Tanya Hutson, who was diagnosed with breast cancer in 2022 and had chemotherapy as part of her treatment, called the new DNA test “absolutely amazing”.

“It just proves what happens when money is put into research,” she said, adding that chemotherapy had been “brutal”.

“For all these people out there who don’t need it but are still getting it – it’s an absolute game changer.”

It is not known whether the findings apply to people under the age of 40, with a result still several years away, according to UCL.

BBC